Exelixis, Inc.
EXELExelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.
Drugs in Pipeline
7
Phase 3 Programs
6
Upcoming Catalysts
2
Next Catalyst
Next month
Market Overview
Stock performance and key metrics
2 upcoming, 0 past
Regorafenib
Colorectal Cancer
XL184
Glioblastoma Multiforme
Cabozantinib
Solid Tumors
XL092
Non-Clear Cell Renal Cell Carcinoma
Zanzalintinib
Head and Neck Squamous Cell Carcinoma
Cabozantinib tablets
Renal Cell Carcinoma
XL820
Gastrointestinal Stromal Tumors
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Regorafenib | Phase 3 | Colorectal Cancer | - | - |
XL184 | Phase 3 | Glioblastoma Multiforme | - | - |
Cabozantinib | Phase 3 | Solid Tumors | - | - |
XL092 | Phase 3 | Non-Clear Cell Renal Cell Carcinoma | - | - |
Zanzalintinib | Phase 3 | Head and Neck Squamous Cell Carcinoma | - | - |
Cabozantinib tablets | Phase 3 | Renal Cell Carcinoma | - | - |
XL820 | Phase 2 | Gastrointestinal Stromal Tumors | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Exelixis, Inc.'s drug pipeline?→
CatalystAlert tracks 7 drug candidates in Exelixis, Inc.'s (EXEL) pipeline across Phase 3, Phase 2. Its lead program is Regorafenib (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Exelixis, Inc.'s next FDA catalyst?→
Exelixis, Inc.'s (EXEL) next tracked catalyst is a Earnings expected November 3, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track EXEL biotech catalysts?→
Add EXEL to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Exelixis, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.